Staphylococcus aureus Infections - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 538
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SA66E2DA97FEN
Leaflet:

Download PDF Leaflet

Staphylococcus aureus Infections - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Staphylococcus Aureus Infections - Pipeline Review, H2 2015’, provides an overview of the Staphylococcus Aureus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Staphylococcus Aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Staphylococcus Aureus Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Staphylococcus Aureus Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Staphylococcus Aureus Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Staphylococcus Aureus Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Staphylococcus Aureus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Staphylococcus aureus Infections Overview
Therapeutics Development
Staphylococcus aureus Infections - Therapeutics under Development by Companies
Staphylococcus aureus Infections - Therapeutics under Investigation by Universities/Institutes
Staphylococcus aureus Infections - Pipeline Products Glance
Staphylococcus aureus Infections - Products under Development by Companies
Staphylococcus aureus Infections - Products under Investigation by Universities/Institutes
Staphylococcus aureus Infections - Companies Involved in Therapeutics Development
Staphylococcus aureus Infections - Therapeutics Assessment
Drug Profiles
Staphylococcus aureus Infections - Recent Pipeline Updates
Staphylococcus aureus Infections - Dormant Projects
Staphylococcus aureus Infections - Discontinued Products
Staphylococcus aureus Infections - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Staphylococcus aureus Infections, H2 2015
Number of Products under Development for Staphylococcus aureus Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
Staphylococcus aureus Infections - Pipeline by Absynth Biologics Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Actelion Ltd, H2 2015
Staphylococcus aureus Infections - Pipeline by Adenium Biotech ApS, H2 2015
Staphylococcus aureus Infections - Pipeline by AIMM Therapeutics B.V., H2 2015
Staphylococcus aureus Infections - Pipeline by Alchemia Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Allergan Plc, H2 2015
Staphylococcus aureus Infections - Pipeline by AlphaMab Co., Ltd, H2 2015
Staphylococcus aureus Infections - Pipeline by Alvogen Korea, H2 2015
Staphylococcus aureus Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2015
Staphylococcus aureus Infections - Pipeline by AnGes MG, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Aphios Corporation, H2 2015
Staphylococcus aureus Infections - Pipeline by Arsanis Biosciences GmbH, H2 2015
Staphylococcus aureus Infections - Pipeline by AstraZeneca Plc, H2 2015
Staphylococcus aureus Infections - Pipeline by Aureogen Biosciences, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Aurigene Discovery Technologies Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Bharat Biotech International Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by BioDiem Ltd, H2 2015
Staphylococcus aureus Infections - Pipeline by Biomar Microbial Technologies, H2 2015
Staphylococcus aureus Infections - Pipeline by BioSource Pharm, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by C3 Jian, Inc, H2 2015
Staphylococcus aureus Infections - Pipeline by Cellceutix Corporation, H2 2015
Staphylococcus aureus Infections - Pipeline by Cempra, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by ContraFect Corporation, H2 2015
Staphylococcus aureus Infections - Pipeline by CrystalGenomics, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by CSA Biotechnologies LLC , H2 2015
Staphylococcus aureus Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Debiopharm International S.A., H2 2015
Staphylococcus aureus Infections - Pipeline by DesignMedix, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Destiny Pharma Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Dong-A Socio Group, H2 2015
Staphylococcus aureus Infections - Pipeline by Ensol Biosciences Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Evaxion Biotech, H2 2015
Staphylococcus aureus Infections - Pipeline by Excelimmune, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Staphylococcus aureus Infections - Pipeline by Galapagos NV, H2 2015
Staphylococcus aureus Infections - Pipeline by GangaGen Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by GlaxoSmithKline Plc, H2 2015
Staphylococcus aureus Infections - Pipeline by Helix BioMedix, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2015
Staphylococcus aureus Infections - Pipeline by Humabs BioMed SA, H2 2015
Staphylococcus aureus Infections - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015
Staphylococcus aureus Infections - Pipeline by Imaxio SA, H2 2015
Staphylococcus aureus Infections - Pipeline by Immupharma Plc, H2 2015
Staphylococcus aureus Infections - Pipeline by ImmuVen, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Integrated BioTherapeutics, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by iNtRON Biotechnology Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by ioGenetics, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Staphylococcus aureus Infections - Pipeline by Lascco SA, H2 2015
Staphylococcus aureus Infections - Pipeline by LegoChem Biosciences, Inc, H2 2015
Staphylococcus aureus Infections - Pipeline by Lytix Biopharma AS, H2 2015
Staphylococcus aureus Infections - Pipeline by Madam Therapeutics B.V., H2 2015
Staphylococcus aureus Infections - Pipeline by MedImmune, LLC, H2 2015
Staphylococcus aureus Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015
Staphylococcus aureus Infections - Pipeline by Merck & Co., Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by MGB Biopharma Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Microbiotix, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by MorphoSys AG, H2 2015
Staphylococcus aureus Infections - Pipeline by Morphotek, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Motif BioSciences, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Nabriva Therapeutics AG, H2 2015
Staphylococcus aureus Infections - Pipeline by NanoBio Corporation, H2 2015
Staphylococcus aureus Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Novabiotics Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by NovaDigm Therapeutics, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Novan, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015
Staphylococcus aureus Infections - Pipeline by Omnia Molecular Ltd., H2 2015
Staphylococcus aureus Infections - Pipeline by Oragenics, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Pepscan Presto BV, H2 2015
Staphylococcus aureus Infections - Pipeline by Pfizer Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by PharmaIN Corporation, H2 2015
Staphylococcus aureus Infections - Pipeline by Phico Therapeutics Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Phylogica Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Pono Pharma, H2 2015
Staphylococcus aureus Infections - Pipeline by Procarta Biosystems Ltd, H2 2015
Staphylococcus aureus Infections - Pipeline by QureTech Bio AB, H2 2015
Staphylococcus aureus Infections - Pipeline by Redx Pharma Plc, H2 2015
Staphylococcus aureus Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Savara Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Sealife PHARMA GMBH, H2 2015
Staphylococcus aureus Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Soligenix, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Staphylococcus aureus Infections - Pipeline by Syntiron LLC, H2 2015
Staphylococcus aureus Infections - Pipeline by Taejoon Pharm Co., Ltd., H2 2015
Staphylococcus aureus Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Techulon, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Telephus Medical LLC, H2 2015
Staphylococcus aureus Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by TGV-Laboratories, H2 2015
Staphylococcus aureus Infections - Pipeline by Theravance Biopharma, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by United Therapeutics Corporation, H2 2015
Staphylococcus aureus Infections - Pipeline by Valevia UK Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by Varinel, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Wintermute Biomedical LLC, H2 2015
Staphylococcus aureus Infections - Pipeline by Wockhardt Limited, H2 2015
Staphylococcus aureus Infections - Pipeline by XBiotech USA, Inc., H2 2015
Staphylococcus aureus Infections - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Staphylococcus aureus Infections Therapeutics - Recent Pipeline Updates, H2 2015
Staphylococcus aureus Infections - Dormant Projects, H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..1), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..2), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..3), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..4), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..5), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..6), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..7), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..8), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..9), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..10), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..11), H2 2015
Staphylococcus aureus Infections - Dormant Projects (Contd..12), H2 2015
Staphylococcus aureus Infections - Discontinued Products, H2 2015
Staphylococcus aureus Infections - Discontinued Products (Contd..1), H2 2015

LIST OF FIGURES

Number of Products under Development for Staphylococcus aureus Infections, H2 2015
Number of Products under Development for Staphylococcus aureus Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Absynth Biologics Limited
Actelion Ltd
Adenium Biotech ApS
AIMM Therapeutics B.V.
Alchemia Limited
Allergan Plc
AlphaMab Co., Ltd
Alvogen Korea
AmpliPhi Biosciences Corporation
AnGes MG, Inc.
Aphios Corporation
Arsanis Biosciences GmbH
AstraZeneca Plc
Aureogen Biosciences, Inc.
Aurigene Discovery Technologies Limited
Bharat Biotech International Limited
BioDiem Ltd
Biomar Microbial Technologies
BioSource Pharm, Inc.
C3 Jian, Inc
Cellceutix Corporation
Cempra, Inc.
ContraFect Corporation
CrystalGenomics, Inc.
CSA Biotechnologies LLC
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
DesignMedix, Inc.
Destiny Pharma Limited
Dong-A Socio Group
Ensol Biosciences Inc.
Evaxion Biotech
Excelimmune, Inc.
F. Hoffmann-La Roche Ltd.
Galapagos NV
GangaGen Inc.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Hsiri Therapeutics, LLC
Humabs BioMed SA
Ildong Pharmaceutical Co., Ltd.
Imaxio SA
Immupharma Plc
ImmuVen, Inc.
Integrated BioTherapeutics, Inc.
iNtRON Biotechnology Inc.
ioGenetics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lascco SA
LegoChem Biosciences, Inc
Lytix Biopharma AS
Madam Therapeutics B.V.
MedImmune, LLC
Melinta Therapeutics, Inc
Merck & Co., Inc.
MGB Biopharma Limited
Microbiotix, Inc.
MicuRx Pharmaceuticals, Inc.
MorphoSys AG
Morphotek, Inc.
Motif BioSciences, Inc.
Nabriva Therapeutics AG
NanoBio Corporation
NovaBay Pharmaceuticals, Inc.
Novabiotics Limited
NovaDigm Therapeutics, Inc.
Novan, Inc.
NovoBiotic Pharmaceuticals, LLC
Omnia Molecular Ltd.
Oragenics, Inc.
Pepscan Presto BV
Pfizer Inc.
PharmaIN Corporation
Phico Therapeutics Limited
Phylogica Limited
Pono Pharma
Procarta Biosystems Ltd
QureTech Bio AB
Redx Pharma Plc
Sarepta Therapeutics, Inc.
Savara Inc.
Sealife PHARMA GMBH
Sentinella Pharmaceuticals, Inc.
Soligenix, Inc.
Sorrento Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syntiron LLC
Taejoon Pharm Co., Ltd.
TAXIS Pharmaceuticals, Inc.
Techulon, Inc.
Telephus Medical LLC
Tetraphase Pharmaceuticals Inc.
TGV-Laboratories
Theravance Biopharma, Inc.
United Therapeutics Corporation
Valevia UK Limited
Varinel, Inc.
Wintermute Biomedical LLC
Wockhardt Limited
XBiotech USA, Inc.
Yungjin Pharm. Co., Ltd.
Skip to top


Ask Your Question

Staphylococcus aureus Infections - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: